{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:12:43Z","timestamp":1790097163952,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100010109","name":"Medical University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100010109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatologie"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>\n                    Sexuell \u00fcbertragbare Infektionen (STI) nehmen deutlich zu. Die Inzidenz von Infektionen mit\n                    <jats:italic>Neisseria gonorrhoeae<\/jats:italic>\n                    (NG) ist laut den rezentesten ECDC-Daten in den letzten 10\u00a0Jahren um mehr als 300\u202f% angestiegen. Au\u00dferdem nehmen Resistenzen sowohl bei NG und einem anderen STI-Erreger,\n                    <jats:italic>Mycoplasma genitalium<\/jats:italic>\n                    (MG), stetig zu. Multiresistente St\u00e4mme (\u201eSuperbugs\u201c) stellen im klinischen Alltag eine gr\u00f6\u00dfer werdende Herausforderung dar. Im Folgenden wird eine Literatur\u00fcbersicht rezenter Studien und aktueller Leitlinien vorgestellt. NG zeigt weltweit hohe Resistenzraten gegen\u00fcber Penizillinen, Tetracyclinen und Fluorchinolonen sowie zunehmend auch eine reduzierte Empfindlichkeit gegen\u00fcber dem Makrolidantibiotikum Azithromycin. Die Resistenzraten gegen\u00fcber Ceftriaxon, der derzeitigen Erstlinientherapie, sind in Europa weiterhin sehr gering. Im s\u00fcdostasiatischen Raum wurde zuletzt jedoch ein deutlicher Anstieg von Ceftriaxon-Resistenzen bei NG beobachtet. Bei MG werden global steigende Resistenzen v.\u00a0a. gegen\u00fcber Makroliden und seltener Fluorchinolonen beobachtet. Eine kombinierte Resistenz von MG gegen beide Wirkstoffklassen ist keine Seltenheit mehr und erfordert regelm\u00e4\u00dfig den Einsatz von Reserveantibiotika wie Pristinamycin oder Sitafloxacin. Zusammenfassend ist festzuhalten, dass die zunehmende Resistenzentwicklung bei NG und MG ein relevantes globales Gesundheitsproblem darstellt. Verst\u00e4rkte \u00dcberwachung, molekulare Resistenzdiagnostik und gezielter Ansatz sowohl von Testungen als auch der Antibiotikatherapie sind entscheidend f\u00fcr eine nachhaltige Infektionskontrolle.\n                  <\/jats:p>","DOI":"10.1007\/s00105-026-05650-0","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T10:42:54Z","timestamp":1772448174000},"page":"232-241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Superbugs Neisseria gonorrhoeae und Mycoplasma genitalium"],"prefix":"10.1007","volume":"77","author":[{"given":"Angelika","family":"Kogler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chromy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Sadoghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"3","key":"5650_CR1","first-page":"287","volume":"17","author":"S Buder","year":"2019","unstructured":"Buder\u00a0S, Sch\u00f6fer\u00a0H, Meyer\u00a0T, Bremer\u00a0V, Kohl\u00a0PK, Skaletz-Rorowski\u00a0A et\u00a0al (2019) Bacterial sexually transmitted infections. J\u00a0Dtsch Dermatol Ges 17(3):287\u2013315","journal-title":"J Dtsch Dermatol Ges"},{"key":"5650_CR2","doi-asserted-by":"crossref","unstructured":"Du M, Yan W, Jing W, Qin C, Liu Q, Liu M, et\u00a0al. Increasing incidence rates of sexually transmitted infections from 2010 to 2019: an analysis of temporal trends by geographical regions and age groups from the 2019 Global Burden of Disease Study. BMC Infect Dis. 2022 Dec 1;22(1).","DOI":"10.1186\/s12879-022-07544-7"},{"key":"5650_CR3","unstructured":"Syphilis - Annual Epidemiological Report for 2023. [cited 2025 Nov 23]; Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/syphilis-annual-epidemiological-report-2023"},{"key":"5650_CR4","unstructured":"Gonorrhoea - Annual Epidemiological Report for 2023. [cited 2025 Nov 23]; Available from: https:\/\/www.ecdc.europa.eu\/en\/publications-data\/gonorrhoea-annual-epidemiological-report-2023"},{"key":"5650_CR5","doi-asserted-by":"crossref","unstructured":"Spiteri G, Unemo M, M\u00e5rdh O, Amato-Gauci AJ. The resurgence of syphilis in high-income countries in the 2000s: a\u00a0focus on Europe. Epidemiol Infect. 2019;147.","DOI":"10.1017\/S0950268819000281"},{"issue":"21","key":"5650_CR6","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMra1907194","volume":"382","author":"DA Williamson","year":"2020","unstructured":"Williamson\u00a0DA, Chen\u00a0MY (2020) Emerging and Reemerging Sexually Transmitted Infections. N Engl J Med 382(21):2023\u20132032","journal-title":"N Engl J Med"},{"issue":"3","key":"5650_CR7","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/nrurol.2016.268","volume":"14","author":"M Unemo","year":"2017","unstructured":"Unemo\u00a0M, Jensen\u00a0JS (2017) Antimicrobial-resistant sexually transmitted infections: gonorrhoea and Mycoplasma genitalium. Nat Rev Urol 14(3):139\u2013152","journal-title":"Nat Rev Urol"},{"issue":"7","key":"5650_CR8","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41579-024-01023-3","volume":"22","author":"JS Jensen","year":"2024","unstructured":"Jensen\u00a0JS, Unemo\u00a0M (2024) Antimicrobial treatment and resistance in sexually transmitted bacterial infections. Nat Rev Microbiol 22(7):435\u2013450","journal-title":"Nat Rev Microbiol"},{"key":"5650_CR9","doi-asserted-by":"crossref","unstructured":"Unemo M, Seifert HS, Hook EW, Hawkes S, Ndowa F, Dillon JAR. Gonorrhoea. Nat Rev Dis Prim. 2019 Dec 1;5(1).","DOI":"10.1038\/s41572-019-0128-6"},{"key":"5650_CR10","doi-asserted-by":"crossref","unstructured":"Ross J, Guaschino S, Cusini M, Jensen J. 2017 European guideline for the management of pelvic inflammatory disease.","DOI":"10.1177\/0956462417744099"},{"issue":"2","key":"5650_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/jdv.20029","volume":"39","author":"A Kogler","year":"2025","unstructured":"Kogler\u00a0A, Sadoghi\u00a0B, Draschl\u00a0A, Chromy\u00a0D, Binder\u00a0L, Schiefer-Niederkorn\u00a0A et\u00a0al (2025) Prevalence of Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium at pharyngeal and anorectal sites in patients presenting to an STI outpatient ward. J\u00a0Eur Acad Dermatol Venereol 39(2):389\u2013397","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5650_CR12","doi-asserted-by":"crossref","unstructured":"Tuddenham\u00a0S, Hamill\u00a0MM, Khalil, Ghanem\u00a0G, Hopkins\u00a0J, Ghanem\u00a0KG (2022) Diagnosis and Treatment of Sexually Transmitted Infections: A Review. JAMA 327(2):161\u2013172","DOI":"10.1001\/jama.2021.23487"},{"key":"5650_CR13","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-S\u00e1nchez M, Ong JJ, Fairley CK, Chen MY, Williamson DA, Maddaford K, et\u00a0al. Clinical presentation of asymptomatic and symptomatic heterosexual men who tested positive for urethral gonorrhoea at a\u00a0sexual health clinic in Melbourne, Australia. BMC Infect Dis. 2020 Jul 8;20(1).","DOI":"10.1186\/s12879-020-05197-y"},{"key":"5650_CR14","doi-asserted-by":"crossref","unstructured":"Unemo M, Ross JDC, Serwin AB, Gomberg M, Cusini M, Jensen JS. 2020 European guideline for the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS. 2020;","DOI":"10.1177\/0956462420949126"},{"issue":"15","key":"5650_CR15","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1097\/QAD.0000000000003067","volume":"35","author":"MR Stenger","year":"2021","unstructured":"Stenger\u00a0MR, Pathela\u00a0P, Schumacher\u00a0C, Burghardt\u00a0N, Amiya\u00a0R, Madera\u00a0R et\u00a0al (2021) Trends in HIV prevalence by self-report among MSM diagnosed and reported with gonorrhea in six United States jurisdictions from 2010 to 2019. AIDS 35(15):2523\u20132530","journal-title":"AIDS"},{"key":"5650_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr7004a1","volume":"70","author":"KA Workowski","year":"2021","unstructured":"Workowski\u00a0KA, Bachmann\u00a0LH, Chan\u00a0PA, Johnston\u00a0CM, Muzny\u00a0CA, Park\u00a0I et\u00a0al (2021) Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports 70:1\u2013187","journal-title":"MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports"},{"issue":"2","key":"5650_CR17","first-page":"254","volume":"23","author":"RN Werner","year":"2025","unstructured":"Werner\u00a0RN, Vader\u00a0I, Abunijela\u00a0S, Bickel\u00a0M, Biel\u00a0A, Boesecke\u00a0C et\u00a0al (2025) German evidence- and consensus-based guideline on the management of penile urethritis. J\u00a0Dtsch Dermatol Ges 23(2):254\u2013275","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"5650_CR18","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/sextrans-2024-056165","volume":"100","author":"P Vanbaelen","year":"2024","unstructured":"Vanbaelen\u00a0P, Kenyon\u00a0C (2024) Primum non-nocere: Is it time to stop screening for Neisseria gonorrhoeae and Chlamydia trachomatis in men who have sex with men taking HIV pre-exposure prophylaxis? Sex Transm Infect 100(6):337\u2013338","journal-title":"Sex Transm Infect"},{"issue":"4","key":"5650_CR19","doi-asserted-by":"publisher","first-page":"e233","DOI":"10.1016\/S2352-3018(23)00299-0","volume":"11","author":"T Vanbaelen","year":"2024","unstructured":"Vanbaelen\u00a0T, Tsoumanis\u00a0A, Florence\u00a0E, Van Dijck\u00a0C, Huis in \u2019t Veld\u00a0D, Sauvage\u00a0AS et\u00a0al (2024) Effect of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on incidence of these infections in men who have sex with men and transgender women taking HIV pre-exposure prophylaxis (the Gonoscreen study): results from a randomised, multicentre, controlled trial. lancet HIV 11(4):e233\u2013e244","journal-title":"lancet HIV"},{"issue":"0","key":"5650_CR20","volume":"0","author":"V T","year":"2025","unstructured":"Vanbaelen\u00a0T, De Baetselier\u00a0I, Tsoumanis\u00a0A, Hensen\u00a0B, Kenyon\u00a0C (2025) Effect of decreasing the frequency of screening for Neisseria gonorrhoeae and Chlamydia trachomatis on the incidence of these infections and antimicrobial use among men who have sex with men using HIV PrEP in Belgium: a retrospective cohort study. The Lancet Microbe 0(0):101214","journal-title":"The Lancet Microbe"},{"issue":"4","key":"5650_CR21","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1136\/sextrans-2017-053384","volume":"94","author":"L Baumann","year":"2018","unstructured":"Baumann\u00a0L, Cina\u00a0M, Egli-Gany\u00a0D, Goutaki\u00a0M, Halbeisen\u00a0FS, Lohrer\u00a0GR et\u00a0al (2018) Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis. Sex Transm Infect 94(4):255\u2013262","journal-title":"Sex Transm Infect"},{"issue":"7","key":"5650_CR22","doi-asserted-by":"publisher","first-page":"E2127","DOI":"10.1093\/cid\/ciaa1832","volume":"73","author":"B Ber\u00e7ot","year":"2021","unstructured":"Ber\u00e7ot\u00a0B, Charreau\u00a0I, Rousseau\u00a0C, Delaugerre\u00a0C, Chidiac\u00a0C, Pialoux\u00a0G et\u00a0al (2021) High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men Who Have Sex With Men: A Substudy of the ANRS IPERGAY Pre-exposure Prophylaxis Trial. Clin Infect Dis 73(7):E2127\u2013E2133","journal-title":"Clin Infect Dis"},{"issue":"5","key":"5650_CR23","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1007\/s15010-024-02261-6","volume":"52","author":"D Chromy","year":"2024","unstructured":"Chromy\u00a0D, Starossek\u00a0L, Grabmeier-Pfistershammer\u00a0K, Adamek\u00a0S, Maischack\u00a0F, Sammet\u00a0S et\u00a0al (2024) High cure rates of Mycoplasma genitalium following empiric treatment with azithromycin alongside frequent detection of macrolide resistance in Austria. Infection 52(5):1921\u20131930","journal-title":"Infection"},{"issue":"3","key":"5650_CR24","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1093\/infdis\/jis356","volume":"206","author":"AC Se\u00f1a","year":"2012","unstructured":"Se\u00f1a\u00a0AC, Lensing\u00a0S, Rompalo\u00a0A, Taylor\u00a0SN, Martin\u00a0DH, Lopez\u00a0LM et\u00a0al (2012) Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis infections in men with nongonococcal urethritis: predictors and persistence after therapy. J\u00a0Infect Dis 206(3):357\u2013365","journal-title":"J Infect Dis"},{"issue":"5","key":"5650_CR25","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1111\/jdv.17972","volume":"36","author":"JS Jensen","year":"2022","unstructured":"Jensen\u00a0JS, Cusini\u00a0M, Gomberg\u00a0M, Moi\u00a0H, Wilson\u00a0J, Unemo\u00a0M (2022) 2021 European guideline on the management of Mycoplasma genitalium infections. J\u00a0Eur Acad Dermatol Venereol 36(5):641\u2013650","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"5650_CR26","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10096-022-04521-5","volume":"42","author":"MD Perry","year":"2023","unstructured":"Perry\u00a0MD, Jones\u00a0S, Bertram\u00a0A, de Salazar\u00a0A, Barrientos-Dur\u00e1n\u00a0A, Schiettekatte\u00a0G et\u00a0al (2023) The prevalence of Mycoplasma genitalium (MG) and Trichomonas vaginalis (TV) at testing centers in Belgium, Germany, Spain, and the UK using the cobas TV\/MG molecular assay. Eur J Clin Microbiol Infect Dis 42(1):43\u201352","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"5650_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100779","volume":"33","author":"JJ Ong","year":"2021","unstructured":"Ong\u00a0JJ, Ruan\u00a0L, Lim\u00a0AG, Bradshaw\u00a0CS, Taylor-Robinson\u00a0D, Unemo\u00a0M et\u00a0al (2021) Impact of screening on the prevalence and incidence of Mycoplasma genitalium and its macrolide resistance in men who have sex with men living in Australia: A mathematical model. EClinicalMedicine 33:100779","journal-title":"EClinicalMedicine"},{"issue":"8","key":"5650_CR28","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1016\/S1473-3099(20)30171-7","volume":"20","author":"AC Se\u00f1a","year":"2020","unstructured":"Se\u00f1a\u00a0AC, Bachmann\u00a0L, Johnston\u00a0C, Wi\u00a0T, Workowski\u00a0K, Hook\u00a0EW et\u00a0al (2020) Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction. Lancet Infect Dis 20(8):e181\u2013e191","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"5650_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.idc.2023.02.009","volume":"37","author":"GE Wood","year":"2023","unstructured":"Wood\u00a0GE, Bradshaw\u00a0CS, Manhart\u00a0LE (2023) Update in Epidemiology and Management of Mycoplasma genitalium Infections. Infect Dis Clin North Am 37(2):311\u2013333","journal-title":"Infect Dis Clin North Am"},{"key":"5650_CR30","doi-asserted-by":"crossref","unstructured":"Soni S, Fifer H, Al-Shakarchi Y, Bassett J, Mbaulu J, Pinto-Sander N, et\u00a0al. British Association of Sexual Health and HIV National guideline for the management of infection with Mycoplasma genitalium, 2025. Int J STD AIDS. 2025;","DOI":"10.1177\/09564624251359054"},{"issue":"3","key":"5650_CR31","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos\u00a0AP, Srinivasan\u00a0A, Carey\u00a0RB, Carmeli\u00a0Y, Falagas\u00a0ME, Giske\u00a0CG et\u00a0al (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268\u2013281","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"5650_CR32","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/S1473-3099(25)00118-5","volume":"25","author":"H Sati","year":"2025","unstructured":"Sati\u00a0H, Carrara\u00a0E, Savoldi\u00a0A, Hansen\u00a0P, Garlasco\u00a0J, Campagnaro\u00a0E et\u00a0al (2025) The WHO Bacterial Priority Pathogens List 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance. Lancet Infect Dis 25(9):1033\u20131043","journal-title":"Lancet Infect Dis"},{"key":"5650_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2025.101318","volume":"54","author":"S Jacobsson","year":"2025","unstructured":"Jacobsson\u00a0S, Cole\u00a0MJ, Schr\u00f6der\u00a0D, Jansen van Rensburg\u00a0M, Day\u00a0M, K\u00f6dm\u00f6n\u00a0C et\u00a0al (2025) Antimicrobial resistance in Neisseria gonorrhoeae and its risk groups in 23 European countries in 2022 within the European Gonococcal Antimicrobial Surveillance Programme (Euro-GASP): a retrospective observational study. Lancet Reg Heal - Eur 54:101318","journal-title":"Lancet Reg Heal - Eur"},{"key":"5650_CR34","doi-asserted-by":"crossref","unstructured":"Hooshiar MH, Sholeh M, Beig M, Azizian K, Kouhsari E. Global trends of antimicrobial resistance rates in Neisseria gonorrhoeae: a\u00a0systematic review and meta-analysis. Front Pharmacol. 2024;15.","DOI":"10.3389\/fphar.2024.1284665"},{"key":"5650_CR35","unstructured":"RKI - Gonokokken-Resistenz-Surveillance [Internet]. [cited 2025 Nov 16]. Available from: https:\/\/www.rki.de\/DE\/Themen\/Forschung-und-Forschungsdaten\/Sentinels-Surveillance-Panel\/Gonokokken\/gonokokken-resistenz-surveillance-node.html"},{"key":"5650_CR36","doi-asserted-by":"crossref","unstructured":"Geusau A, Chromy D, Heissenberger D, Lippert K, Eder C, Heger F, et\u00a0al. Resistance profiles of Neisseria gonorrhoeae isolates in Vienna, Austria: a\u00a0phenotypic and genetic characterization from 2013 to 2020. Int J Antimicrob Agents. 2022 Nov 1;60(5\u20136).","DOI":"10.1016\/j.ijantimicag.2022.106656"},{"issue":"4","key":"5650_CR37","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jac\/dkaa526","volume":"76","author":"J Yan","year":"2021","unstructured":"Yan\u00a0J, Chen\u00a0Y, Yang\u00a0F, Ling\u00a0X, Jiang\u00a0S, Zhao\u00a0F et\u00a0al (2021) High percentage of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone among isolates from a single hospital in Hangzhou, China. J\u00a0Antimicrob Chemother 76(4):936\u2013939","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"5650_CR38","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1093\/infdis\/jiaf071","volume":"232","author":"JGE Laumen","year":"2025","unstructured":"Laumen\u00a0JGE, Hieu\u00a0VN, Nhung\u00a0PH, Vandelannoote\u00a0K, Nguyen\u00a0TT, Nguyen\u00a0TT et\u00a0al (2025) High Prevalence of Ceftriaxone-Resistant Neisseria gonorrhoeae in Hanoi, Vietnam, 2023\u20132024. J\u00a0Infect Dis 232(1):e73\u2013e77","journal-title":"J Infect Dis"},{"key":"5650_CR39","doi-asserted-by":"crossref","unstructured":"Pleininger S, Indra A, Golparian D, Heger F, Schindler S, Jacobsson S, et\u00a0al. Extensively drug-resistant (XDR) Neisseria gonorrhoeae causing possible gonorrhoea treatment failure with ceftriaxone plus azithromycin in Austria, April 2022. Euro Surveill. 2022 Jun 16;27(24).","DOI":"10.2807\/1560-7917.ES.2022.27.24.2200455"},{"issue":"9","key":"5650_CR40","doi-asserted-by":"publisher","DOI":"10.3201\/eid3009.240557","volume":"30","author":"F Cam\u00e9l\u00e9na","year":"2024","unstructured":"Cam\u00e9l\u00e9na\u00a0F, M\u00e9rim\u00e8che\u00a0M, Brousseau\u00a0J, Mainardis\u00a0M, Verger\u00a0P, Le Risb\u00e9\u00a0C et\u00a0al (2024) Emergence of Extensively Drug-Resistant Neisseria gonorrhoeae, France, 2023. Emerg Infect Dis 30(9):1903","journal-title":"Emerg Infect Dis"},{"issue":"11","key":"5650_CR41","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1093\/jac\/dkac281","volume":"77","author":"R Pitt","year":"2022","unstructured":"Pitt\u00a0R, Boampong\u00a0D, Day\u00a0M, Jensen\u00a0JS, Cole\u00a0M (2022) Challenges of in vitro propagation and antimicrobial susceptibility testing of Mycoplasma genitalium. J\u00a0Antimicrob Chemother 77(11):2901\u20132907","journal-title":"J Antimicrob Chemother"},{"issue":"11","key":"5650_CR42","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/S1473-3099(20)30154-7","volume":"20","author":"DA Machalek","year":"2020","unstructured":"Machalek\u00a0DA, Tao\u00a0Y, Shilling\u00a0H, Jensen\u00a0JS, Unemo\u00a0M, Murray\u00a0G et\u00a0al (2020) Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. Lancet Infect Dis 20(11):1302\u20131314","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"5650_CR43","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00103-025-04052-2","volume":"68","author":"R Dumke","year":"2025","unstructured":"Dumke\u00a0R (2025) Infections with the human pathogenic Mycoplasma species M. genitalium and M. pneumoniae: Current epidemiological aspects. Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz 68(8):932\u2013939","journal-title":"Bundesgesundheitsblatt - Gesundheitsforsch - Gesundheitsschutz"},{"key":"5650_CR44","doi-asserted-by":"crossref","unstructured":"Chua TP, Vodstrcil LA, Murray GL, Plummer EL, Jensen JS, Unemo M, et\u00a0al. Evolving patterns of macrolide and fluoroquinolone resistance in Mycoplasma genitalium: an updated systematic review and meta-analysis. The Lancet Microbe. 2025 Jul 1;6(7).","DOI":"10.1016\/j.lanmic.2024.101047"},{"key":"5650_CR45","unstructured":"Stary A (2021) THERAPIELEITLINIEN GONORRHOE 2021. https:\/\/www.oegstd.at\/net\/images\/doc\/leitlinien\/Leitlinien-Gonorrhoe_Update2021.pdf. Accessed 16.11.2025"},{"key":"5650_CR46","unstructured":"Leitfaden STI-Therapie, -Diagnostik und -Pr\u00e4vention Deutsche STI-Gesellschaft Gesellschaft zur F\u00f6rderung der Sexuellen Gesundheit."},{"issue":"2","key":"5650_CR47","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1001\/jama.2021.23487","volume":"327","author":"S Tuddenham","year":"2022","unstructured":"Tuddenham\u00a0S, Hamill\u00a0MM, Ghanem\u00a0KG (2022) Diagnosis and Treatment of Sexually Transmitted Infections: A Review. JAMA - J Am Med Assoc 327(2):161\u2013172","journal-title":"JAMA - J Am Med Assoc"},{"key":"5650_CR48","unstructured":"Stary A. Therapieleitlinien Gonorrhoe 2021."},{"key":"5650_CR49","doi-asserted-by":"crossref","unstructured":"Tsoumanis A, Van Dijck C, Hens N, Kenyon C. Switching From Dual to Monotherapy for Gonorrhea is Associated With a\u00a0Halving of Gonococcal Resistance to Azithromycin\u2014A Modelling Study of MSM in Belgium. Open Forum Infect Dis. 2025 May 31;12(6).","DOI":"10.1093\/ofid\/ofaf320"},{"issue":"5","key":"5650_CR50","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1093\/jac\/dkae063","volume":"79","author":"M Unemo","year":"2024","unstructured":"Unemo\u00a0M, Golparian\u00a0D, Oxelbark\u00a0J, Kong\u00a0FYS, Brown\u00a0D, Louie\u00a0A et\u00a0al (2024) Pharmacodynamic evaluation of ceftriaxone single-dose therapy (0.125\u20131\u202fg) to eradicate ceftriaxone-susceptible and ceftriaxone-resistant Neisseria gonorrhoeae strains in a\u00a0hollow fibre infection model for gonorrhoea. J\u00a0Antimicrob Chemother 79(5):1006\u20131013","journal-title":"J Antimicrob Chemother"},{"issue":"12","key":"5650_CR51","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1093\/jac\/dkae369","volume":"79","author":"H Fifer","year":"2024","unstructured":"Fifer\u00a0H, Doumith\u00a0M, Rubinstein\u00a0L, Mitchell\u00a0L, Wallis\u00a0M, Singh\u00a0S et\u00a0al (2024) Ceftriaxone-resistant Neisseria gonorrhoeae detected in England, 2015-24: an observational analysis. J\u00a0Antimicrob Chemother 79(12):3332\u20133339","journal-title":"J Antimicrob Chemother"},{"issue":"19","key":"5650_CR52","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","volume":"379","author":"SN Taylor","year":"2018","unstructured":"Taylor\u00a0SN, Marrazzo\u00a0J, Batteiger\u00a0BE, Hook\u00a0EW, Se\u00f1a\u00a0AC, Long\u00a0J et\u00a0al (2018) Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. N Engl J Med 379(19):1835\u20131845","journal-title":"N Engl J Med"},{"issue":"10489","key":"5650_CR53","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1016\/S0140-6736(25)00628-2","volume":"405","author":"JDC Ross","year":"2025","unstructured":"Ross\u00a0JDC, Wilson\u00a0J, Workowski\u00a0KA, Taylor\u00a0SN, Lewis\u00a0DA, Gatsi\u00a0S et\u00a0al (2025) Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. Lancet (London, England) 405(10489):1608\u20131620","journal-title":"Lancet (London, England)"},{"key":"5650_CR54","doi-asserted-by":"crossref","unstructured":"Waites KB, Crabb DM, Xiao L, Duffy LB. In Vitro Activities of Gepotidacin (GSK2140944) and Other Antimicrobial Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob Agents Chemother. 2017;61(10).","DOI":"10.1128\/AAC.01064-17"},{"issue":"1","key":"5650_CR55","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1080\/22221751.2020.1775498","volume":"9","author":"JS Jensen","year":"2020","unstructured":"Jensen\u00a0JS, N\u00f8rgaard\u00a0C, Scangarella-Oman\u00a0N, Unemo\u00a0M (2020) In vitro activity of the first-in-class triazaacenaphthylene gepotidacin alone and in combination with doxycycline against drug-resistant and -susceptible Mycoplasma genitalium. Emerg Microbes Infect 9(1):1388\u20131392","journal-title":"Emerg Microbes Infect"},{"issue":"9","key":"5650_CR56","doi-asserted-by":"publisher","DOI":"10.1099\/jmm.0.001429","volume":"70","author":"TP Chua","year":"2021","unstructured":"Chua\u00a0TP, Bodiyabadu\u00a0K, Machalek\u00a0DA, Garland\u00a0SM, Bradshaw\u00a0CS, Plummer\u00a0EL et\u00a0al (2021) Prevalence of Mycoplasma genitalium fluoroquinolone-resistance markers, and dual-class-resistance markers, in asymptomatic men who have sex with men. J\u00a0Med Microbiol 70(9):001429","journal-title":"J Med Microbiol"},{"issue":"9","key":"5650_CR57","doi-asserted-by":"publisher","first-page":"e267","DOI":"10.1016\/S1473-3099(21)00629-0","volume":"22","author":"EL Sweeney","year":"2022","unstructured":"Sweeney\u00a0EL, Bradshaw\u00a0CS, Murray\u00a0GL, Whiley\u00a0DM (2022) Individualised treatment of Mycoplasma genitalium infection-incorporation of fluoroquinolone resistance testing into clinical care. Lancet Infect Dis 22(9):e267\u2013e270","journal-title":"Lancet Infect Dis"},{"key":"5650_CR58","doi-asserted-by":"crossref","unstructured":"Ring A, Balakrishna S, Imkamp F, Burkard S, Triet F, Brunschweiler F, et\u00a0al. High Rates of Asymptomatic Mycoplasma genitalium Infections With High Proportion of Genotypic Resistance to First-Line Macrolide Treatment Among Men Who Have Sex With Men Enrolled in the Zurich Primary HIV Infection Study. Open Forum Infect Dis. 2022 Jun 1;9(6).","DOI":"10.1093\/ofid\/ofac217"}],"container-title":["Die Dermatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00105-026-05650-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-026-05650-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T07:02:13Z","timestamp":1774335733000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00105-026-05650-0"}},"subtitle":["Therapeutische Herausforderungen durch antimikrobielle Resistenzen","Therapeutic challenges driven by antimicrobial resistance"],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["5650"],"URL":"https:\/\/doi.org\/10.1007\/s00105-026-05650-0","relation":{},"ISSN":["2731-7005","2731-7013"],"issn-type":[{"value":"2731-7005","type":"print"},{"value":"2731-7013","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Kogler, D.\u00a0Chromy und B.\u00a0Sadoghi geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien. F\u00fcr Bildmaterial oder anderweitige Angaben innerhalb des Manuskripts, \u00fcber die Patient\/-innen zu identifizieren sind, liegt von ihnen und\/oder ihren gesetzlichen Vertretern\/Vertreterinnen eine schriftliche Einwilligung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}